Reasons for Lack of Referral to Medical Oncology for Systemic Therapy in Stage Iv Non-small-cell Lung Cancer: Comparison of 2003–2006 with 2010–2011 | Zendy

Jenny J. Ko | Zendy; R. Tudor | Zendy; H. Li | Zendy; Mei-Fang Liu | Zendy; Kate Skolnik | Zendy; William K Boland | Zendy; James Macklow | Zendy; Don Morris | Zendy; D. Gwyn Bebb | Zendy

Open Access

Reasons for Lack of Referral to Medical Oncology for Systemic Therapy in Stage Iv Non-small-cell Lung Cancer: Comparison of 2003–2006 with 2010–2011

Author(s) -

Jenny J. Ko,

R. Tudor,

H. Li,

Mei-Fang Liu,

Kate Skolnik,

William K Boland,

James Macklow,

Don Morris,

D. Gwyn Bebb

Publication year - 2017

Publication title -

current oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.053

H-Index - 51

eISSN - 1718-7729

pISSN - 1198-0052

DOI - 10.3747/co.24.3691

Subject(s) - medicine , systemic therapy , lung cancer , referral , stage (stratigraphy) , oncology , cancer , intensive care medicine , family medicine , breast cancer , biology , paleontology

Only approximately 25% of stage iv non-small-cell lung cancer (nsclc) patients receive systemic therapy. For such patients, we examined factors affecting referral to a cancer centre (cc) and to medical oncology (mo), and use of systemic therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research